All In Biotech

Free tool

FAERS Monitor: Wynzora

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213422 or its brand name (Wynzora, Betamethasone Dipropionate, Calcipotriene). Reports on generic versions are filed under their own applications.

Reports

428

Serious

296

69% of reports

Hospitalization

107

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • psoriasis123
  • drug ineffective70
  • pruritus53
  • fatigue40
  • pain37
  • arthralgia33
  • diarrhoea32
  • rash31
  • nasopharyngitis30
  • inappropriate schedule of product administration29
  • psoriatic arthropathy29
  • cellulitis26
  • headache26
  • pneumonia26
  • erythema25

Reports by year received

View as table
YearReports
201011
201216
20141
20151
201639
201738
201834
201950
202049
202138
202247
202346
202428
202514
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,731 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriasisSignal12346.339.95,438
psoriatic arthropathySignal2935.124.7929
cellulitisSignal2625.417.5586
nasopharyngitisSignal308.05.7178
inappropriate schedule of product administrationSignal297.95.6170
pruritusSignal536.85.3260
erythemaSignal256.04.1100
pneumoniaSignal263.92.755
arthralgiaSignal333.92.870
rashSignal313.52.554
painSignal373.02.247
drug ineffectiveSignal702.62.172
fatigueSignal402.51.937
diarrhoeaSignal322.41.726
headacheSignal262.01.413

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.